Qureight, a UK-based AI imaging company developing quantitative imaging solutions for clinical trials in lung and heart diseases, has raised $20 million in funding led by Molten Ventures, with participation from existing investors Hargreave Hale AIM VCT, XTX Ventures, Guinness Ventures, Meltwind, and Ascension. The investment will accelerate the expansion of the company’s AI-powered imaging platform and support commercial growth in new therapeutic areas.
Expanding AI Disease Models
The funding will support the launch of an AI imaging laboratory built around Qureight’s 3D chest imaging foundation model. The platform is designed to reduce the time and data required to develop new disease models, enabling expansion beyond lung fibrosis into asthma, pulmonary hypertension, bronchiectasis, and drug-induced lung toxicity.
Qureight also plans to strengthen its commercial team and broaden adoption of its regulatory-compliant imaging platform, which provides imaging CRO services, AI-powered lung biomarkers, and data science tools such as synthetic control arms to improve clinical trial efficiency.
"The global lung and heart clinical trials market is expected to grow to USD $27.5bn by 2030, with a CAGR of 6.9% over the next six years. We are strategically positioning ourselves to address this market with our end-to-end, integrated imaging platform for clinical trials. We are excited to bring on Molten Ventures to lead this new financing round and for Dr Inga Deakin to join our Board of Directors. I also welcome Anna Salim of Hargreave Hale to the Board, and thank all of our existing investors who participated in this round. Their ongoing support reflects the confidence in both our enterprise-grade imaging platform, and our world class team, to address a critical demand to accelerate clinical trials. Expanding our 3D imaging deep learning models with our new AI laboratory will complement our existing dominance in lung fibrosis, allow us to enter new markets, and solidify our leadership position in the lung and heart imaging CRO market." — Dr Muhunthan Thillai, Co-founder and CEO, Qureight
Accelerating Clinical Research
Qureight’s platform is already used by biopharma companies to deliver real-time imaging insights and precision endpoints for clinical trials in fibrotic lung diseases. The company aims to expand these capabilities across additional respiratory and cardiovascular indications while improving trial design and reducing development costs.
"Qureight demonstrates how AI, powered by real-world data, can accelerate discovery and transform clinical research. The team’s rapid deployment of solutions in areas of unmet need underscores their unique capability to drive the next generation of medical innovation. We look forward to working with Muhunthan and the team as they deliver on this vision." — Dr Inga Deakin, Partner, Molten Ventures